VISUFARMA SPA
Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
The Usefulness of Visuprime in Cataract Surgery
- Conditions
- Cataract
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- VISUfarma SpA
- Target Recruit Count
- 75
- Registration Number
- NCT06533995
- Locations
- 🇮🇹
Policlinico Casilino, Rome, RM, Italy
🇮🇹Clinica Fabia Mater, Rome, RM, Italy
VISUPRIME® Eye Drops
- Conditions
- Proliferative Diabetic RetinopathyDiabetic Macular EdemaMacular Edema of Right Retina (Diagnosis)Macular Degeneration, Age RelatedMyopic Choroidal Neovascularisation
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- VISUfarma SpA
- Target Recruit Count
- 78
- Registration Number
- NCT05677685
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, BA, Italy
🇮🇹Ospedale Santa Maria della Misericordia, Perugia, PG, Italy
🇮🇹Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, RM, Italy
Clinical Investigation to Assess the Efficacy and the Safety of VisuXL® Gel Administered in Patients Affected by Moderate DED
- Conditions
- Dry Eye Syndromes
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- VISUfarma SpA
- Target Recruit Count
- 90
- Registration Number
- NCT04485533
- Locations
- 🇫🇷
Hôpital Morvan, Brest, Finistère, France
🇮🇹ASST-Santi Paolo e Carlo-Presidio San Paolo, Milano, MI, Italy
🇪🇸Hospital Clínico San Carlos de Madrid, Madrid, Spain
Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD
- Conditions
- AMD
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- VISUfarma SpA
- Target Recruit Count
- 160
- Registration Number
- NCT04177069
- Locations
- 🇮🇹
Casa di Cura Villa dei Fiori, Acerra, Napoli, Italy
🇮🇹Ospedale Felice Lotti, Pontedera, Pisa, Italy
🇮🇹ASST Spedali Civili di Brescia, Brescia, Italy
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
- Conditions
- Glaucoma, Open-Angle
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- VISUfarma SpA
- Target Recruit Count
- 70
- Registration Number
- NCT04038034
- Locations
- 🇮🇹
UO Oculistica - PO Cisanello, Pisa, PI, Italy
🇮🇹U.O. di Oculistica, Fondazione Policlinico Agostino A. Gemelli,, Rome, Italy
- Prev
- 1
- 2
- Next